Send to

Choose Destination
See comment in PubMed Commons below
Thromb Haemost. 2002 Sep;88(3):387-8.

Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease.

Author information

  • 1Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, UK.


We describe four patients with von Willebrand's disease (VWD) who experienced venous thrombosis after treatment with an intermediate purity factor VIII (FVIII) concentrate (Haemate P3) was used to cover invasive or surgical procedures. Most patients had additional risk factors for venous thromboembolism (VTE) and it is difficult to be certain of the contribution of the concentrate to the VTE. In view of the recognised association between high factor VIII activity (FVIII:C) levels and VTE there is a physiological basis for this complication and it is important to consider this when administering FVIII containing concentrates to VWD patients.

Comment in

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Schattauer Verlag
    Loading ...
    Support Center